GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) E10: ₹47.47 (As of Mar. 2026)


NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
73 GF Score
Price ₹2,354.80
GF Value ₹2,614.23
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals E10?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO -0.50% 73 E10 is ₹47.47 as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 73/100 and a GF Value™ of ₹2,614.23 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹16.400. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹47.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GlaxoSmithKline Pharmaceuticals's average E10 Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), GlaxoSmithKline Pharmaceuticals's current stock price is ₹2354.80. GlaxoSmithKline Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was ₹47.47. GlaxoSmithKline Pharmaceuticals's Shiller PE Ratio of today is 49.61.

During the past 13 years, the highest Shiller PE Ratio of GlaxoSmithKline Pharmaceuticals was 79.21. The lowest was 44.67. And the median was 59.88.


GlaxoSmithKline Pharmaceuticals  (NSE:GLAXO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GlaxoSmithKline Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=2354.80/47.47
=49.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of GlaxoSmithKline Pharmaceuticals was 79.21. The lowest was 44.67. And the median was 59.88.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


GlaxoSmithKline Pharmaceuticals E10 Related Terms


GlaxoSmithKline Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals E10 Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 43.70 47.47

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.70 44.42 45.66 46.68 47.47

NSE:GLAXO vs LLY, JNJ, ABBV: E10 Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Shiller PE Ratio falls into.


NSE:GLAXO
73GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.4/164.2724*164.2724
=16.400

Current CPI (Mar. 2026) = 164.2724.

GlaxoSmithKline Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201112 0.000 75.359 0.000
201212 0.000 83.774 0.000
201312 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201706 1.560 107.109 2.393
201803 0.000 109.786 0.000
201806 4.960 111.317 7.320
201809 5.950 115.142 8.489
201812 6.710 115.142 9.573
201903 8.660 118.202 12.035
201906 6.700 120.880 9.105
201909 29.680 123.175 39.583
201912 -39.030 126.235 -50.790
202003 8.150 124.705 10.736
202006 6.540 127.000 8.459
202009 4.510 130.118 5.694
202012 9.240 130.889 11.597
202103 0.840 131.771 1.047
202106 7.150 134.084 8.760
202109 12.060 135.847 14.584
202112 8.880 138.161 10.558
202203 71.960 138.822 85.153
202206 7.040 142.347 8.124
202209 11.420 144.661 12.968
202212 9.710 145.763 10.943
202303 7.880 146.865 8.814
202306 7.810 150.280 8.537
202309 12.840 151.492 13.923
202312 2.700 152.924 2.900
202403 11.480 153.035 12.323
202406 10.760 155.789 11.346
202409 14.910 157.882 15.513
202412 13.570 158.323 14.080
202503 15.520 157.552 16.182
202506 12.100 159.755 12.442
202509 15.200 162.289 15.386
202512 17.450 163.281 17.556
202603 16.400 164.272 16.400

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹47.47 mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a E10 of ₹47.47 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' E10 too high?
GlaxoSmithKline Pharmaceuticals' current E10 is ₹47.47. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' E10 compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' E10 of ₹47.47 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current E10 is ₹47.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,614.23, compared to a current price of ₹2,354.80 — trading 9.9% below its estimated fair value. The current E10 is ₹47.47. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current E10 is ₹47.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,354.80 is trading 9.9% below its estimated GF Value™ of ₹2,614.23. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:GLAXO:

  • E10: ₹47.47
  • GF Value™: ₹2,614.23 vs. price of ₹2,354.80 (9.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score

Get the complete analysis for NSE:GLAXO

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,354.80
Price
₹2,614.23
GF Value